Clinical Trial Update: An Open-Label Pilot Trial of Alpha Lipoic Acid (ALA) for Weight Loss in Schizophrenia [NA]

View source ↗

Summary

An open-label pilot trial evaluated alpha-lipoic acid for weight loss in individuals with schizophrenia. The study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Schizophrenia

Drugs mentioned

• Alpha Lipoic Acid (alpha-lipoic acid)

Snippet

Sponsor: Yale University | Conditions: Obesity, Weight Loss | NA | Status: COMPLETED